TW202525342A - 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體 - Google Patents

玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體 Download PDF

Info

Publication number
TW202525342A
TW202525342A TW113133330A TW113133330A TW202525342A TW 202525342 A TW202525342 A TW 202525342A TW 113133330 A TW113133330 A TW 113133330A TW 113133330 A TW113133330 A TW 113133330A TW 202525342 A TW202525342 A TW 202525342A
Authority
TW
Taiwan
Prior art keywords
group
hyaluronic acid
acid derivative
molecular weight
kda
Prior art date
Application number
TW113133330A
Other languages
English (en)
Chinese (zh)
Inventor
藪内昂平
宮本佳季
福本圭介
勝又徹
中川慶之
Original Assignee
日商旭化成股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商旭化成股份有限公司 filed Critical 日商旭化成股份有限公司
Publication of TW202525342A publication Critical patent/TW202525342A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW113133330A 2020-02-07 2021-02-04 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體 TW202525342A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020019963 2020-02-07
JP2020-019963 2020-02-07
JP2020111674 2020-06-29
JP2020-111674 2020-06-29

Publications (1)

Publication Number Publication Date
TW202525342A true TW202525342A (zh) 2025-07-01

Family

ID=77199974

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113133330A TW202525342A (zh) 2020-02-07 2021-02-04 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體
TW110104263A TWI888483B (zh) 2020-02-07 2021-02-04 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110104263A TWI888483B (zh) 2020-02-07 2021-02-04 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體

Country Status (6)

Country Link
US (1) US20230066990A1 (https=)
EP (1) EP4101860A4 (https=)
JP (2) JPWO2021157665A1 (https=)
CN (3) CN118027246A (https=)
TW (2) TW202525342A (https=)
WO (1) WO2021157665A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI834948B (zh) * 2020-02-05 2024-03-11 日商旭化成股份有限公司 玻尿酸衍生物組合物、醫藥組合物及玻尿酸衍生物－藥物結合體組合物
CN116410346A (zh) * 2021-12-31 2023-07-11 华熙生物科技股份有限公司 一种还原性透明质酸酯及其制备方法
CN115403681A (zh) * 2022-05-13 2022-11-29 宁波格鲁康生物科技有限公司 生物安全注射用改性透明质酸、制备方法及其在美容整形注射材料上的应用
KR20240164786A (ko) * 2022-05-31 2024-11-20 아사히 가세이 가부시키가이샤 히알루론산 유도체, 의약 조성물 및 의약 조성물의 제조 방법
CA3262434A1 (en) * 2022-07-20 2025-06-12 Asahi Kasei Kabushiki Kaisha Hyaluronic acid derivative drug composition and drug composition
JP2024041256A (ja) * 2022-09-14 2024-03-27 旭化成株式会社 化粧料
CN117607297A (zh) * 2023-11-24 2024-02-27 天津键凯科技有限公司 一种基于sec-mals法检测peg修饰的透明质酸的方法
CN121270753A (zh) * 2024-10-12 2026-01-06 华熙生物科技股份有限公司 植醇-透明质酸复合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3051215B2 (ja) * 1991-08-27 2000-06-12 株式会社資生堂 ヒアルロン酸ゲル及びその製造方法
JP2005139409A (ja) * 2003-11-10 2005-06-02 Medicaraise Corp デルマタン硫酸の製法
CN101020724A (zh) * 2006-02-14 2007-08-22 镇江东方生物工程设备技术有限责任公司 一种低分子量透明质酸钠的制备方法
JP5043364B2 (ja) 2006-05-01 2012-10-10 生化学工業株式会社 多糖誘導体の製造方法
US8759322B2 (en) * 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
CZ2012842A3 (cs) * 2012-11-27 2014-08-20 Contipro Biotech S.R.O. Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití
CN103435718B (zh) * 2013-08-21 2016-12-28 中国药科大学 Peg修饰的透明质酸胆固醇酯
US11104813B2 (en) 2015-06-02 2021-08-31 Asahi Kasei Kabushiki Kaisha Dispersion
EP3456745B1 (en) * 2016-05-11 2021-08-25 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivatives into which cationic groups and hydrophobic groups are introduced
US11512147B2 (en) * 2017-11-15 2022-11-29 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative modified with polyethylene glycol
JP2020111674A (ja) 2019-01-11 2020-07-27 住友ゴム工業株式会社 タイヤ
WO2020158771A1 (ja) * 2019-01-29 2020-08-06 国立大学法人三重大学 がんワクチン製剤
TWI834948B (zh) * 2020-02-05 2024-03-11 日商旭化成股份有限公司 玻尿酸衍生物組合物、醫藥組合物及玻尿酸衍生物－藥物結合體組合物

Also Published As

Publication number Publication date
TW202140073A (zh) 2021-11-01
CN118108876A (zh) 2024-05-31
WO2021157665A1 (ja) 2021-08-12
EP4101860A1 (en) 2022-12-14
CN118027246A (zh) 2024-05-14
JP2024054248A (ja) 2024-04-16
JPWO2021157665A1 (https=) 2021-08-12
EP4101860A4 (en) 2023-07-19
CN114945600A (zh) 2022-08-26
US20230066990A1 (en) 2023-03-02
TWI888483B (zh) 2025-07-01

Similar Documents

Publication Publication Date Title
TWI888483B (zh) 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體
JP5542687B2 (ja) ヒアルロン酸誘導体、およびその医薬組成物
US11564971B2 (en) Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
JP5060131B2 (ja) 水溶性ヒアルロン酸修飾物の製造方法
WO2008136536A1 (ja) 化学架橋ヒアルロン酸誘導体を含むハイブリッドゲルおよびそれを用いた医薬組成物
WO2017195880A1 (ja) カチオン性基および疎水性基が導入されたヒアルロン酸誘導体
TWI834948B (zh) 玻尿酸衍生物組合物、醫藥組合物及玻尿酸衍生物－藥物結合體組合物
JP7641129B2 (ja) ヒアルロン酸誘導体組成物、医薬組成物及びヒアルロン酸誘導体－薬物結合体組成物
JP2022044579A (ja) 点眼剤
JP2022013861A (ja) ヒアルロン酸誘導体組成物
JP7641130B2 (ja) ヒアルロン酸誘導体組成物、医薬組成物及びヒアルロン酸誘導体－薬物結合体組成物
WO2025070791A1 (ja) ヒアルロン酸誘導体、ヒアルロン酸誘導体架橋ゲル、及び医薬組成物
TW202600172A (zh) 載體組合物
HK1205525B (en) Hyaluronic acid derivative having amino acid and steryl group introduced thereinto